These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16335926)

  • 21. Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
    Patankar SJ; Jurs PC
    J Chem Inf Comput Sci; 2003; 43(3):885-99. PubMed ID: 12767147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
    He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
    J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interpretation of scoring functions using 3D molecular fields. Mapping the diacyl-hydrazine-binding pocket of an insect ecdysone receptor.
    Bordas B; Belai I; Lopata A; Szanto Z
    J Chem Inf Model; 2007; 47(1):176-85. PubMed ID: 17238263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors.
    Nair PC; Sobhia ME
    J Mol Graph Model; 2007 Jul; 26(1):117-23. PubMed ID: 17140831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D-QSAR and molecular docking studies of 1,3,5-triazene-2,4-diamine derivatives against r-RNA: novel bacterial translation inhibitors.
    Sekhar YN; Nayana MR; Sivakumari N; Ravikumar M; Mahmood SK
    J Mol Graph Model; 2008 Jun; 26(8):1338-52. PubMed ID: 18372201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein-based alignment in 3D-QSAR of FBPase inhibitors.
    Yi P; Di YT; Liu W; Hao XJ; Ming Y; Huang DS; Yang J; Yi ZZ; Li ZJ; Yang RD; Zhang JC
    Eur J Med Chem; 2011 Mar; 46(3):885-92. PubMed ID: 21269737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based CoMFA as a predictive model - CYP2C9 inhibitors as a test case.
    Yasuo K; Yamaotsu N; Gouda H; Tsujishita H; Hirono S
    J Chem Inf Model; 2009 Apr; 49(4):853-64. PubMed ID: 19391630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational studies of COX-2 inhibitors: 3D-QSAR and docking.
    Kim HJ; Chae CH; Yi KY; Park KL; Yoo SE
    Bioorg Med Chem; 2004 Apr; 12(7):1629-41. PubMed ID: 15028256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    Du J; Lei B; Qin J; Liu H; Yao X
    J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
    Lee JH; Kang NS; Yoo SE
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A CoMFA study of COX-2 inhibitors with receptor based alignment.
    Datar PA; Coutinho EC
    J Mol Graph Model; 2004 Dec; 23(3):239-51. PubMed ID: 15530820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
    Peng Y; Keenan SM; Zhang Q; Welsh WJ
    J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular inhibition of protein tyrosine phosphatase 1B by uncharged thioxothiazolidinone derivatives.
    Stuible M; Zhao L; Aubry I; Schmidt-Arras D; Böhmer FD; Li CJ; Tremblay ML
    Chembiochem; 2007 Jan; 8(2):179-86. PubMed ID: 17191286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of protein tyrosine phosphatase-1B inhibitors.
    Black E; Breed J; Breeze AL; Embrey K; Garcia R; Gero TW; Godfrey L; Kenny PW; Morley AD; Minshull CA; Pannifer AD; Read J; Rees A; Russell DJ; Toader D; Tucker J
    Bioorg Med Chem Lett; 2005 May; 15(10):2503-7. PubMed ID: 15863305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity.
    Navarrete-Vazquez G; Paoli P; León-Rivera I; Villalobos-Molina R; Medina-Franco JL; Ortiz-Andrade R; Estrada-Soto S; Camici G; Diaz-Coutiño D; Gallardo-Ortiz I; Martinez-Mayorga K; Moreno-Díaz H
    Bioorg Med Chem; 2009 May; 17(9):3332-41. PubMed ID: 19362487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors.
    Pan J; Liu GY; Cheng J; Chen XJ; Ju XL
    Eur J Med Chem; 2010 Mar; 45(3):967-72. PubMed ID: 19969397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR.
    Chen G; Luo X; Zhu W; Luo C; Liu H; Puah CM; Chen K; Jiang H
    Bioorg Med Chem; 2004 May; 12(9):2409-17. PubMed ID: 15080937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.